Blocking c-myc and stat3 by E. coli expressed and enzyme digested siRNA in mouse melanoma

Biochemical and Biophysical Research Communications

Volumn 348, Issue 2, 2006, Pages 600-605

  Hong, Jie ^a   Zhao, Yingchun ^a   Huang, Weida ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

B16 melanoma; Combined treatment; esiRNA; RNA interference

Indexed keywords

MYC PROTEIN; SMALL INTERFERING RNA; STAT3 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ESCHERICHIA COLI; FEMALE; INTERMETHOD COMPARISON; MELANOMA; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; ESCHERICHIA COLI; MELANOMA, EXPERIMENTAL; MICE; PROTO-ONCOGENE PROTEINS C-MYC; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR;

EID: 33746922662     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.07.107     Document Type: Article

References (31)

1. Murakami H., Sanderson N.D., Nagy P., Marino P.A., Merlino G., and Thorgeirsson S.S. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumourigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res. 53 (1993) 1719-1723
2. Valentina M.F., Andras K., Joseph T.W., Peter J.W., and Snorri S.T. Disruption of Redox Homeostasis in the Transforming Growth Factor-a/c-myc Transgenic Mouse Model of Accelerated Hepatocarcinogenesis. The Journal of Biological Chemistry 273 (1998) 15846-15853
3. Richard J. Preface: STAT signaling. Oncogene 19 (2000) 2466-2467
4. Shirogane T., Fukada T., Muller J.M., Shima D.T., Hibi M., and Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 11 (1999) 709-719
5. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., and Darnell J.E. Stat3 as an oncogene. Cell 98 (1999) 295-303
6. James T., and Richard J. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19 (2000) 6613-6626
7. Guilian N., Richard H., and Robyn C.F. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumour in vivo. Cancer Res. 59 (1999) 5059-5063
8. Zamore P.D., Tuschl T., Sharp P.A., and Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101 (2000) 25-33
9. Hammond S.M., Bernstein E., Beach D., and Hannon G.J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404 (2000) 293-296
10. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
11. Caplen N.J., Parrish S., Imani F., Fire A., and Morgan R.A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 98 (2001) 9742-9747
12. Milhavet O., Gary D.S., and Mattson M.P. RNA interference in biology and medicine. Pharmacol. Rev. 55 (2003) 629-648
13. Lieberman J., Song E., Lee S.K., and Shankar P. Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol. Med. 9 (2003) 397-403
14. Raymond M.S., Aslam A., and Jun X. Cancer siRNA therapy by tumour selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32 (2004) e149
15. Van W.R., Prins J., Meijer C., Uges D.R., De V.E., and Mulder N.H. Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Anticancer Res. 16 (1996) 1963-1970
16. Kerbel R.S., Yu J., and Tran J. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastas. Rev. 20 (2001) 79-86
17. Miller K.D., Sweeney C.J., and Sledge G.W. The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann. Oncol. 14 (2003) 20-28
18. Xin Z., Zhuo C., and Mi S.C. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin. Cancer. Res. 11 (2005) 6261-6269
19. Qian Z.K., Xuan B.Q., and Min T.S. Cost-effective method of siRNA preparation and its application to inhibit hepatitis B virus replication in HepG2 cells. World J. Gastroenterol. 11 (2005) 1297-1302
20. Xuan B., Qian Z., Tan C., Min T., Shen S., and Huang W. esiRNAs purified with chromatography suppress homologous gene expression with high efficiency and specificity. Mol. Biotechnol. 31 (2005) 203
21. Xu X.M., Chen Y., and Chen J. A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis. Cancer Res. 63 (2003) 5685-5690
22. Raeymaekers L. Quantitative PCR: theoretical considerations with practical implications. Anal. Biochem. 214 (1993) 582-585
23. Laird N.M., and Ware J.H. Random effects models for longitudinal data. Biometrics 38 (1982) 963-974
24. Romina P., Sigal K., Dalia B.L., and Linda Z.P. Cancer therapeutics: targeting the dark side of Myc. Eur. J. Cancer 41 (2005) 2485-2501
25. Heikkila R., Schwab G., and Wickstrom E. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 328 (1987) 445-449
26. Roussel M.F. Key effectors of signal transduction and G1 progression. Adv. Cancer. Res. 74 (1998) 1-24
27. Adachi S., Obaya A.J., and Han Z. c-Myc is necessary for DNA damage-induced apoptosis in the G (2) phase of the cell cycle. Mol. Cell. Biol. 21 (2001) 4929-4937
28. Lin Z., Nuo Y., Alisha M.H., Stephen C.R., and George C. Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem. Biophys. Res. Commun. 30 (2003) 1169-1178
29. Kaiyi L., Shiaw Y.L., Charles F.B., and Philip S. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res. 63 (2003) 3593-3597
30. Stewart D.A., Thomas S.D., Mayfield C.A., and Miller D.M. Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression. Nucleic Acids Res. 30 (2002) 2565-2574
31. Stewart D.A., Thomas S.D., Mayfield C.A., and Miller D.M. Psoralen-modified clamp-forming antisense oligonucleotides reduce cellular c-Myc protein expression and B16-F0 proliferation. Nucleic Acids Res. 29 (2001) 4052-4061